Lifeline Biotechnologies Valuation
| LLBO Stock | USD 0.0001 0.0003 75.00% |
Lifeline Biotechnologies seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Lifeline Biotechnologies from analyzing the firm fundamentals such as Cash And Equivalents of 603.32 K, current valuation of 4.25 M, and Debt To Equity of 0.08 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Lifeline Biotechnologies' price fluctuation is out of control at this time. Calculation of the real value of Lifeline Biotechnologies is based on 3 months time horizon. Increasing Lifeline Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lifeline Biotechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lifeline Pink Sheet. However, Lifeline Biotechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 9.6E-5 | Hype 9.1E-5 |
The intrinsic value of Lifeline Biotechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lifeline Biotechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lifeline Biotechnologies helps investors to forecast how Lifeline pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lifeline Biotechnologies more accurately as focusing exclusively on Lifeline Biotechnologies' fundamentals will not take into account other important factors: Lifeline Biotechnologies Total Value Analysis
Lifeline Biotechnologies is now forecasted to have valuation of 4.25 M with market capitalization of 10.99 M, debt of 448.07 K, and cash on hands of 603.32 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lifeline Biotechnologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.25 M | 10.99 M | 448.07 K | 603.32 K |
Lifeline Biotechnologies Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Lifeline suggests not a very effective usage of assets in December.Lifeline Biotechnologies Profitability Analysis
Net Loss for the year was (574.27 K) with profit before overhead, payroll, taxes, and interest of 0.About Lifeline Biotechnologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lifeline Biotechnologies. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lifeline Biotechnologies based exclusively on its fundamental and basic technical indicators. By analyzing Lifeline Biotechnologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lifeline Biotechnologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lifeline Biotechnologies. We calculate exposure to Lifeline Biotechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lifeline Biotechnologies's related companies.Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Lifeline Biotechnologies, Inc. is headquartered in Reno, Nevada. Lifeline Biotech operates under Medical Devices classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Lifeline Biotechnologies' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Lifeline Biotechnologies' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Lifeline Biotechnologies' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Lifeline Biotechnologies' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Lifeline Biotechnologies' revenue streams: Identify Lifeline Biotechnologies' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Lifeline Biotechnologies' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Lifeline Biotechnologies' growth potential: Evaluate Lifeline Biotechnologies' management, business model, and growth potential.
- Determine Lifeline Biotechnologies' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Lifeline Biotechnologies' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Lifeline Biotechnologies Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Retained Earnings | -12.2 M |
Other Information on Investing in Lifeline Pink Sheet
Lifeline Biotechnologies financial ratios help investors to determine whether Lifeline Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lifeline with respect to the benefits of owning Lifeline Biotechnologies security.